Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.

Slides:

Advertisements

Similar presentations

Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.

Advertisements

Hollie Shaner-McRae DNP RN FAAN

National Patient Safety Goal 3E:

VTE in abdominal-pelvic surgery patients

+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.

Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.

Prophylaxis of Venous Thromboembolism

Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.

Venous Thromboembolism

RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.

Best Practices in Meeting NPSG 3E-Anticoagulation Requirements MaryAnne Cronin, PharmD Assistant Director of Pharmacy Glen Cove Hospital.

DVT Prophylaxis in Medical Patients Rog Kyle, MD MUSC 6/5/12.

 When untreated, general postsurgical patients risk for Deep Venous Thrombosis (DVT) is 19%-25% (Buckner, et al., 2013).  Post surgical orthopedic patients.

Fundamental Research in Oncology and Thrombosis Cancer and thrombosis – a complex relationship lCancer may increase the risk of thrombosis through multiple.

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

Prevention Of Venous Thromboembolism In The Cancer Surgical Patient A K Kakkar Barts and the London School of Medicine and Thrombosis Research Institute,

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.

IMPLEMENTING GUIDELINES AND REDUCING PATIENT RISK OF VENOUS THROMBOEMBOLISM IN A LARGE UK TEACHING HOSPITAL Sharron Millen, Head of Clinical Pharmacy and.

Venous Thromboembolism

Cancer-Associated Thrombosis

The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.

Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.

Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,

Dr. Meg-angela Christi Amores

ST CATHERINE’S HOSPICE Primary thromboprophylaxis in advanced disease MJ Johnson.

VTE prevention and anticoagulation practice VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis Nurse RCHT.

Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?

Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.

Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,

Risk Assessment for VTE. Which of the following best describes you?

Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.

Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.

Mandatory Training: VTE prevention and anticoagulation practice Mandatory Training: VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis.

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.

Educational Purposes. Coalition To Prevent VTE - Risk Assessment.

Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement Eriksson BI, Borris L, Dahl.

Maile Parker, MSIV University of Washington School of Medicine Sept. 27, 2012 Venous Thromboembolism Prophylaxis in Pediatric Patients With Central Venous.

Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline.

Dr Thomas Lloyd F1 Dr Aman Hargehandewal Wrexham Maelor Hospital

Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.

Dr. Lesbia Adalgisa Rodriguez PGY3-Cook County Loyola Family Medicine Residency Program Venous Thromboembolism Prophylaxis in the Inpatient Setting.

Venous thrombosis , why should I care ?

The VERITY Steering Committee

Venous Thromboembolism Prophylaxis (VTE)

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Copyright © 2003 American Medical Association. All rights reserved.

D-dimer and helical CT-PA based diagnostic algorithm for PE

Fig. 2. Comparative efficacy of thromboprophylaxis interventions in the prevention of deep vein thrombosis (DVT). (A) Estimated odds ratios (ORs) and 95%

Assessing the uptake of national initiatives

Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon

Copyright © 2012 American Medical Association. All rights reserved.

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Outpatient Venous Thromboembolism Prophylaxis in Lower Limb Injuries:

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Owen N. Johnson, MD, David L

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Don't look now! Risk stratify first

Succinct Review of the New VTE Prevention and Management Guidelines

Extraordinary Cases of VTE Prevention in Patients With Cancer

Cancer-Associated Thrombosis

How I treat cancer-associated venous thromboembolism

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Presentation transcript:

Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey

FRONTLINE 1 Survey – Rationale FRONTLINE (Fundamental Research in Oncology and Thrombosis) was the first comprehensive global survey of thrombosis and cancer Key objectives –To collect data on the perceived risk and patterns of practice with regard to VTE in cancer patients undergoing surgical and medical management –To provide information on international, and regional practice patterns, allowing for the design of research studies to answer the concerns of practising clinicians Kakkar AK, et al. Oncologist. 2003;8:381 ‒ Trousseau A. Clinique médicale de l’hôtel Dieu de Paris, 2 nd ed. Paris:JB Ballere et Fils 1865.

FRONTLINE 1 Survey – Design The survey, developed under the guidance of an advisory board, included separate sections relating to: –Surgical patients –Medical patients –Thrombosis associated with vascular access devices Questionnaire (available in seven languages) was distributed between July and November 2001 and responses were elicited via paper-based questionnaire and a dedicated website Oncologists were recruited by a series of mailings, advertisements and congress activities 3891 completed responses were received from 74 countries Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

FRONTLINE 1 Survey demographics of respondents Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. Response breakdownParameter Number of responses3891 Survey type (% respondents)Paper-based87 Web-based 13 Survey breakdown (number) Surgical patients1882 Medical patients2640 Catheter use3714 Case study2541 Region (% respondents)Western Europe45 Eastern Europe/Russia10 North America19 Rest of the World22 Not stated4 Practice setting (% respondents) Academic/University53 Community/District46

Perceptions of risk by cancer type >20% risk of VTE without prophylaxis (surgical patients) VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Perceptions of risk by cancer type >20% risk of VTE without prophylaxis (medical patients) VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Patterns of thromboprophylaxis in surgical patients Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Main reasons for not giving prophylaxis in surgical patients VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Proportion of medical patients receiving prophylaxis (overall) Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents Percentage of patients

Proportion of medical patients receiving prophylaxis by cancer type Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Approach to thromboprophylaxis in surgical and medical patients % Respondents AC: anticoagulant; LMWH: low molecular weight heparin; UFH: unfractionated heparin. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Typical duration of thromboprophylaxis in surgical and medical patients % Respondents Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Thromboprophylaxis by region (surgical patients) % Respondents LMWH: low molecular weight heparin; UFH: unfractionated heparin. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Thromboprophylaxis by region (medical patients) Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Diagnostic methods for VTE (surgical and medical patients) % Respondents CT: computed tomography; MRI: magnetic resonance imaging; VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Standard initial treatment for VTE (surgical and medical patients) % Respondents DVT: deep vein thrombosis; LMWH: low molecular weight heparin; PE: pulmonary embolism; UFH: unfractionated heparin; VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Standard initial treatment for VTE by region (surgical patients) % Respondents LMWH: low molecular weight heparin; UFH: unfractionated heparin; VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Standard initial treatment for DVT by region (medical patients) DVT: deep vein thrombosis; LMWH: low molecular weight heparin; UFH: unfractionated heparin. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Standard initial treatment for PE by region (medical patients) % Respondents LMWH: low molecular weight heparin; PE: pulmonary embolism; UFH: unfractionated heparin. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Factors that would justify hospitalization in surgical and medical patients % Respondents DVT: deep vein thrombosis; PE: pulmonary embolism; VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Standard long-term anticoagulant after VTE episode (surgical and medical patients) DVT: deep vein thrombosis; LMWH: low molecular weight heparin; PE: pulmonary embolism; VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Standard long-term anticoagulant treatment after VTE episode by region (surgical patients) % Respondents LMWH: low molecular weight heparin; VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Standard long-term anticoagulant treatment after DVT episode by region (medical patients) DVT: deep vein thrombosis; LMWH: low molecular weight heparin. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Standard long-term anticoagulant treatment after PE episode by region (medical patients) % Respondents LMWH: low molecular weight heparin; PE: pulmonary embolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Duration of anticoagulation treatment after VTE episode (surgical and medical patients) DVT: deep vein thrombosis; PE: pulmonary embolism; VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Perception of risk with central venous access devices Association between central venous access and increased risk of thrombosis Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Perception of risk with central venous access devices Likelihood of patients developing thrombosis without prophylaxis by region Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents % Patients

Thromboprophylaxis use in patients with central venous access device by region % Respondents Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Thromboprophylaxis in patients with a central venous line by region AC: anticoagulant; Adj: adjuvant; LMWH: low molecular weight heparin; sc UFH: subcutaneous unfractionated heparin. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Treatment of thrombosis in patients with a central venous line Removal of line when thrombosis develops Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Treatment of thrombosis in patientd with a central venous line Other therapy % Respondents LMWH: low molecular weight heparin; UFH: unfractionated heparin. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.

Duration of treatment after thrombosis in a patient with central venous line/device Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388. % Respondents

Conclusions FRONTLINE-1 survey demonstrated the wide variations in treatment patterns and practice FRONTLINE-1 survey identified a need for guidelines to direct clinical practice in line with evidence-based data concerning cancer and VTE FRONTLINE-1 survey identified a need for further research on strategies for VTE prevention and treatment in cancer patients, including: –Primary prophylaxis in medically managed patients –Optimum management of VTE in cancer patients –Prevention and treatment of VTE associated with central venous access devices VTE: venous thromboembolism. Kakkar AK, et al. Oncologist. 2003;8:381 ‒ 388.